The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
β-Catenin Activation Promotes Immune Escape and Resistance to Anti–PD-1 Therapy in Hepatocellular Carcinoma
Open accessPublished version of a preprint
Abstract
PD-1 immune checkpoint inhibitors have produced encouraging results in patients with hepatocellular carcinoma (HCC). However, what determines resistance to anti–PD-1 therapies is unclear. We created a novel genetically engineered mouse model of HCC that enables interrogation of how different genetic alterations affect immune surveillance and response to immunotherapies. Expression of exogenous antigens in MYC;Trp53−/− HCCs led to T cell–mediated immune surveillance, which was accompanied by decreased tumor formation and increased survival. Some antigen-expressing MYC;Trp53−/− HCCs escaped the immune system by upregulating the β-catenin (CTNNB1) pathway. Accordingly, expression of exogenous antigens in MYC;CTNNB1 HCCs had no effect, demonstrating that β-catenin promoted immune escape, which involved defective recruitment of dendritic cells and consequently impaired T-cell activity. Expression of chemokine CCL5 in antigen-expressing MYC;CTNNB1 HCCs restored immune surveillance. Finally, β-catenin–driven tumors were resistant to anti–PD-1. In summary, β-catenin activation promotes immune escape and resistance to anti–PD-1 and could represent a novel biomarker for HCC patient exclusion. Significance: Determinants of response to anti–PD-1 immunotherapies in HCC are poorly understood. Using a novel mouse model of HCC, we show that β-catenin activation promotes immune evasion and resistance to anti–PD-1 therapy and could potentially represent a novel biomarker for HCC patient exclusion. See related commentary by Berraondo et al., p. 1003. This article is highlighted in the In This Issue feature, p. 983
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In a mouse model of HCC, activation of WNT–β-catenin signalling promotes immune escape by impairing recruitment of dendritic cells and interfering with recognition by natural killer cells73.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [73]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
featureCounts: an efficient general purpose program for assigning sequence reads to genomic features
Liao, Y., Smyth, G. K., & Shi, W. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt656 · Cited by 27,219
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Self-citationSafety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Self-citationPD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Cited by
Sorted by citations
Items 101–200 of 928
Kim, K. H., Kim, H. K., Kim, H., Kim, C. G., Lee, H., Han, J. W., Choi, S. J., Jeong, S., Jeon, M., Kim, H., et al. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-0427-6 · Cited by 90
Gajos-Michniewicz, A., & Czyz, M. (2024) · Genes & Diseases · doi:10.1016/j.gendis.2023.02.050 · Cited by 89
Morita, M., Nishida, N., Sakai, K., Aoki, T., Chishina, H., Takita, M., Ida, H., Hagiwara, S., Minami, Y., Ueshima, K., et al. (2021) · Liver Cancer · doi:10.1159/000516899 · Cited by 90
Which role for predictors of response to immune checkpoint inhibitors in hepatocellular carcinoma?
Rizzo, A., Cusmai, A., Gadaleta‐Caldarola, G., & Palmiotti, G. (2022) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2022.2064273 · Cited by 87
Danieau, G., Morice, S., Rédiní, F., Verrecchia, F., & Royer, B. B.-L. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20153751 · Cited by 88
Immune Therapy Resistance and Immune Escape of Tumors
Seliger, B., & Massa, C. (2021) · Cancers · doi:10.3390/cancers13030551 · Cited by 84
Liver Inflammation and Hepatobiliary Cancers
Leone, V., Ali, A., Weber, A., Tschaharganeh, D. F., & Heikenwälder, M. F. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.01.012 · Cited by 88
Regulation of Wnt Signaling Pathways at the Plasma Membrane and Their Misregulation in Cancer
Azbazdar, Y., Karabicici, M., Erdal, E., & Özhan, G. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.631623 · Cited by 84
Esteban-Fabró, R., Willoughby, C. E., Piqué‐Gili, M., Montironi, C., Abril‐Fornaguera, J., Peix, J., Torrens, L., Mesropian, A., Balaseviciute, U., Miró‐Mur, F., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2517 · Cited by 83
Self-citationHatanaka, T., Kakizaki, S., Hiraoka, A., Tada, T., Hirooka, M., Kariyama, K., Tani, J., Atsukawa, M., Takaguchi, K., Itobayashi, E., et al. (2022) · Hepatology International · doi:10.1007/s12072-022-10358-z · Cited by 84
Greten, T. F., Abou‐Alfa, G. K., Cheng, A., Duffy, A. G., El-Khoueiry, A. B., Finn, R. S., Galle, P. R., Goyal, L., He, A. R., Kaseb, A. O., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002794 · Cited by 81
Self-citationDigestive cancers: mechanisms, therapeutics and management
Zhan, T., Betge, J., Schulte, N., Dreikhausen, L., Hirth, M., Li, M., Weidner, P., Leipertz, A., Teufel, A., & Ebert, M. P. A. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02097-4 · Cited by 90
Antigen cross-presentation by dendritic cells: A critical axis in cancer immunotherapy
Moussion, C., & Delamarre, L. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101848 · Cited by 82
Immune checkpoint inhibitors in HCC: Cellular, molecular and systemic data
Harkus, U., Wankell, M., Palamuthusingam, P., McFarlane, C., & Hebbard, L. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.01.005 · Cited by 76
Dysfunction of dendritic cells in tumor microenvironment and immunotherapy
Chen, J., Duan, Y.-H., Che, J., & Zhu, J. (2024) · 癌症：英文版 · doi:10.1002/cac2.12596 · Cited by 84
Cooperation Between MYC and β‐Catenin in Liver Tumorigenesis Requires Yap/Taz
Bisso, A., Filipuzzi, M., Figueroa, G. P. G., Brumana, G., Biagioni, F., Doni, M., Ceccotti, G., Tanasković, N., Morelli, M. J., Pendino, V., et al. (2020) · Hepatology · doi:10.1002/hep.31120 · Cited by 77
Bao, R., Stapor, D. C., & Luke, J. J. (2020) · Genome Medicine · doi:10.1186/s13073-020-00787-6 · Cited by 80
Multifaceted Roles of Chemokines and Chemokine Receptors in Tumor Immunity
Matsuo, K., Yoshie, O., & Nakayama, T. (2021) · Cancers · doi:10.3390/cancers13236132 · Cited by 76
Saito, Y., Yin, D., Kubota, N., Wang, X., Filliol, A. A., Remotti, H. E., Nair, A., Fazlollahi, L., Hoshida, Y., Tabas, I. A., et al. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.02.043 · Cited by 82
Spahn, S., Roessler, D., Pompilia, R., Gabernet, G., Gladstone, B. P., Horger, M., Biskup, S., Feldhahn, M., Nahnsen, S., Hilke, F. J., et al. (2020) · Cancers · doi:10.3390/cancers12123830 · Cited by 75
Tran, N. H., Muñoz, S., Thompson, S. M., Hallemeier, C. L., & Bruix, J. (2022) · Hepatology · doi:10.1002/hep.32613 · Cited by 76
Wu, L. Y., Fulgenzi, C. A. M., D’Alessio, A., Cheon, J., Nishida, N., Saeed, A., Wietharn, B., Cammarota, A., Pressiani, T., Personeni, N., et al. (2022) · Cancers · doi:10.3390/cancers14235834 · Cited by 79
Matsumae, T., Kodama, T., Myojin, Y., Maesaka, K., Sakamori, R., Takuwa, A., Oku, K., Motooka, D., Sawai, Y., Oshita, M., et al. (2022) · Cancers · doi:10.3390/cancers14143367 · Cited by 74
Xie, P., Yu, M., Zhang, B., Yu, Q., Zhao, Y., Wu, M., Lei, J., Yan, J., Zhou, B., Liu, S., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.02.009 · Cited by 79
Yu, K.-X., Yuan, W.-J., Wang, H.-Z., & Li, Y. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03675-9 · Cited by 88
APEX1 is a novel diagnostic and prognostic biomarker for hepatocellular carcinoma
Cao, L., Cheng, H., Jiang, Q., Li, H., & Wu, Z. (2020) · Aging · doi:10.18632/aging.102913 · Cited by 71
Feng, G., Hanley, K. L., Liang, Y., & Lin, X. (2020) · Hepatology · doi:10.1002/hep.31479 · Cited by 70
Immunotherapy for hepatocellular carcinoma: Recent advances and future targets
Yu, S. J. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108387 · Cited by 70
Cappuyns, S., Piqué‐Gili, M., Esteban-Fabró, R., Philips, G., Balaseviciute, U., Pinyol, R., Gris‐Oliver, A., Vandecaveye, V., Abril‐Fornaguera, J., Montironi, C., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.12.016 · Cited by 81
Self-citationQiu, X., Zhou, T., Li, S., Wu, J., Tang, J., Ma, G., Yang, S., Hu, J., Wang, K., Shen, S., et al. (2024) · Nature Cancer · doi:10.1038/s43018-024-00824-y · Cited by 74
Yamada, K., Hori, Y., Inoue, S., Yamamoto, Y., Iso, K., Kamiyama, H., Yamaguchi, A., Kimura, T., Uesugi, M., Ito, J., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-0782 · Cited by 71
Wang, J., Xiu, M., Wang, J., Gao, Y., & Li, Y. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01599-6 · Cited by 68
Cadoux, M., Caruso, S., Pham, S., Gougèlet, A., Pophillat, C., Riou, R., Loesch, R., Colnot, S., Nguyễn, C. T., Caldéraro, J., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.01.017 · Cited by 75
HCC and Molecular Targeting Therapies: Back to the Future
Rinaldi, L., Vetrano, E., Rinaldi, B., Galiero, R., Caturano, A., Salvatore, T., & Sasso, F. C. (2021) · Biomedicines · doi:10.3390/biomedicines9101345 · Cited by 66
Yuen, V. W., Chiu, D. K., Law, C., Cheu, J. W., Chan, C. Y., Wong, B. P., Goh, C.-C., Zhang, M. S., Xue, H. D. G., Tse, A. P., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.10.037 · Cited by 67
Wu, Y., Zhang, C., Xiong, J., Cai, D., Wang, C.-Z., Wang, Y., Liu, Y., Wang, Y., Li, Y., Wu, J. H., et al. (2023) · Cell Research · doi:10.1038/s41422-023-00874-4 · Cited by 68
Molecular and immune landscape of hepatocellular carcinoma to guide therapeutic decision-making
Dhanasekaran, R., Suzuki, H., Lemaitre, L., Kubota, N., & Hoshida, Y. (2023) · Hepatology · doi:10.1097/hep.0000000000000513 · Cited by 72
IRGQ-mediated autophagy in MHC class I quality control promotes tumor immune evasion
Herhaus, L., Mato, U. G., Eapen, V. V., Mačinković, I., Bailey, H., Prieto‐Garcia, C., Misra, M., Jacomin, A., Ammanath, A. V., Bagarić, I., et al. (2024) · Cell · doi:10.1016/j.cell.2024.09.048 · Cited by 71
Chen, Z., Soni, N., Piñero, G., Giotti, B., Eddins, D. J., Lindblad, K. E., Ross, J., Vallcorba, M. P., Joshi, T. V., Angione, A., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37361-8 · Cited by 65
Self-citationAoki, T., Nishida, N., Ueshima, K., Morita, M., Chishina, H., Takita, M., Hagiwara, S., Ida, H., Minami, Y., Yamada, A., et al. (2021) · Liver Cancer · doi:10.1159/000518048 · Cited by 63
The effects of MYC on tumor immunity and immunotherapy
Li, J., Dong, T., Wu, Z., Zhu, D., & Gu, H. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01403-3 · Cited by 67
Hu, X., Bao, M., Huang, J., Zhou, L., & Zheng, S. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.541479 · Cited by 61
Drug Treatment for Advanced Hepatocellular Carcinoma: First-Line and Beyond
Feng, Y., Chan, L. L., & Chan, S. L. (2022) · Current Oncology · doi:10.3390/curroncol29080434 · Cited by 61
Ortiz-Barahona, V., Soler, M., Dávalos, V., García-Prieto, C. A., Janin, M., Setién, F., Fernández-Rebollo, I., Bech‐Serra, J. J., de la Torre, C., Guil, S., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01785-z · Cited by 60
Self-citationKudo, M. (2020) · Liver Cancer · doi:10.1159/000509554 · Cited by 61
Taurine enhances the antitumor efficacy of PD-1 antibody by boosting CD8+ T cell function
Yü, P., Shan, J., Liu, Y., Liu, F., Wang, L., Liu, Z., Li, J., Yue, D., Wang, L., Chen, X., et al. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03308-z · Cited by 67
Chen, K., Shuen, T. W. H., & Chow, P. K. H. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02684-w · Cited by 61
Xie, Y., Jiang, J., Tang, Q., Zou, H., Zhao, X., Liu, H., Ma, D., Cai, C., Zhou, Y., Chen, X., et al. (2020) · Advanced Science · doi:10.1002/advs.201903323 · Cited by 58
Leung, C. O. N., Yang, Y., Leung, R. W. H., So, K. K. H., Guo, H. J., Lei, M. M. L., Muliawan, G. K., Gao, Y., Yu, Q. Q., Yun, J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42360-w · Cited by 59
The therapeutic landscape of hepatocellular carcinoma
Gallage, S., Beccaria, M. G., Szydlowska, M., Rahbari, M., Mohr, R. U., Tacke, F., & Heikenwälder, M. F. (2021) · Med · doi:10.1016/j.medj.2021.03.002 · Cited by 61
Lung and lymph node metastases from hepatocellular carcinoma: Comparison of pathological aspects
Woo, H. Y., Rhee, H., Yoo, J. E., Kim, S. H., Choi, G. H., Kim, D. Y., Woo, H. G., Lee, H. S., & Park, Y. N. (2021) · Liver International · doi:10.1111/liv.15051 · Cited by 57
Immunotherapy for hepatocellular carcinoma
Childs, A., Aidoo-Micah, G., Maini, M. K., & Meyer, T. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101130 · Cited by 64
Tong, W., Wang, T., Bai, Y., Yang, X., Han, P., Zhu, L., Zhang, Y., & Shen, Z. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05613-w · Cited by 59
Dai, S., Chen, Y., Cai, W., Dong, S., Zhao, J., Chen, L., & Cheng, C. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01739-6 · Cited by 65
Aoki, T., Kudo, M., Ueshima, K., Morita, M., Chishina, H., Takita, M., Hagiwara, S., Ida, H., Minami, Y., Tsurusaki, M., et al. (2020) · Cancers · doi:10.3390/cancers12103048 · Cited by 55
Yoon, S. J., Combs, J. A., Falzone, A., Prieto-Farigua, N., Caldwell, S., Ackerman, H. D., Flores, E. R., & DeNicola, G. M. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-3000 · Cited by 54
WNT/β-catenin regulatory roles on PD-(L)1 and immunotherapy responses
Mortezaee, K. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01274-z · Cited by 57
Tao, J., Krutsenko, Y., Moghe, A., Singh, S., Poddar, M., Bell, A., Oertel, M., Singhi, A. D., Geller, D., Chen, X., et al. (2021) · Hepatology · doi:10.1002/hep.31730 · Cited by 54
Self-citationWong, A. M., Ding, X., Wong, A. M. G., Xu, M., Zhang, L., Leung, H. H. W., Chan, A. W. H., Song, Q. X., Kwong, J., Chan, L. K., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.03.015 · Cited by 58
Ji, G., Yang, Q., Wang, S., Yan, X., Ou, Q., Gong, L., Zhao, J., Zhou, Y., Tian, F., Lei, J., et al. (2024) · Genome Medicine · doi:10.1186/s13073-024-01320-9 · Cited by 62
Self-citationNishida, N. (2021) · Cancers · doi:10.3390/cancers13153666 · Cited by 56
Cross-Presenting XCR1+ Dendritic Cells as Targets for Cancer Immunotherapy
Audsley, K. M., McDonnell, A. M., & Waithman, J. C. (2020) · Cells · doi:10.3390/cells9030565 · Cited by 54
Systemic treatment for unresectable hepatocellular carcinoma
Leowattana, W., Leowattana, T., & Leowattana, P. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i10.1551 · Cited by 52
Cadherins and catenins in cancer: connecting cancer pathways and tumor microenvironment
Lin, W., Cooper, L. M., & Anastasiadis, P. Z. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1137013 · Cited by 60
Glutamine metabolic reprogramming in hepatocellular carcinoma
Ye, Y., Yu, B., Wang, H., & Yi, F. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1242059 · Cited by 47
MYC in liver cancer: mechanisms and targeted therapy opportunities
Liu, F., Liao, Z., & Zhang, Z. (2023) · Oncogene · doi:10.1038/s41388-023-02861-w · Cited by 53
Cancer immunology data engine reveals secreted AOAH as a potential immunotherapy
Gong, L., Luo, J., Yang, E., Ru, B., Qi, Z., Yang, Y., Rani, A., Purohit, A., Zhang, Y., Guan, G., et al. (2025) · Cell · doi:10.1016/j.cell.2025.07.004 · Cited by 56
Chen, W. S., Liang, Y., Zong, M., Liu, J. J., Kaneko, K., Hanley, K. L., Zhang, K., & Feng, G.-S. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109974 · Cited by 50
Polyploidy control in hepatic health and disease
Sladky, V. C., Eichin, F., Reiberger, T., & Villunger, A. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.06.030 · Cited by 50
Zhu, G., Wang, Y., Wang, B., Liu, W., Dong, S., Chen, E., Cai, J., Wan, J.-L., Du, J.-X., Song, L.-N., et al. (2022) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2022.02.006 · Cited by 50
Mechanisms of drug resistance to immune checkpoint inhibitors in non-small cell lung cancer
Zhou, K., Li, S., Zhao, Y., & Cheng, K. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1127071 · Cited by 49
Precision models in hepatocellular carcinoma
Bárcena‐Varela, M., Monga, S. P., & Lujambio, A. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-01024-w · Cited by 57
Self-citationWnt-Independent and Wnt-Dependent Effects of APC Loss on the Chemotherapeutic Response
Stefanski, C. D., & Prosperi, J. R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21217844 · Cited by 50
Immune Checkpoint Inhibitory Therapy in Sarcomas: Is There Light at the End of the Tunnel?
Siozopoulou, V., Domen, A., Zwaenepoel, K., Beeck, A. V., Smits, E., Pauwels, P., & Marcq, E. (2021) · Cancers · doi:10.3390/cancers13020360 · Cited by 49
Chen, S., Zhang, P., Zhu, G., Wang, B., Cai, J., Song, L., Wan, J.-L., Yang, Y., Du, J.-X., Cai, Y., et al. (2024) · Cellular and Molecular Immunology · doi:10.1038/s41423-024-01231-0 · Cited by 49
Huang, Y., Sheng, H., Xiao, Y., Hu, W., Zhang, Z., Chen, Y., Zhu, Z., Wu, D., Cao, C., & Sun, J. (2021) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2021.06.034 · Cited by 49
Gao, Y., Xu, Q., Li, X., Guo, Y. L., Zhang, B., Jin, Y., Zhu, C., Shen, Y., Yang, P., Shi, Y., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04654-7 · Cited by 47
Tu, Y., Wu, H., Zhong, C., Liu, Y., Xiong, Z., Chen, S., Wang, J., Wong, P. P.-C., Yang, W., Liang, Z., et al. (2024) · Gut · doi:10.1136/gutjnl-2024-332281 · Cited by 50
Chu, T., Zhu, G., Tang, Z., Qu, W., Yang, R., Pan, H., Wáng, Y., Tian, R., Chen, L., Guan, Z., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-62132-y · Cited by 55
Cueto, F. J., del Fresno, C., Brandi, P., Combes, A. J., Hernández-García, E., Sánchez-Paulete, A. R., Enamorado, M., Bromley, C. P., Gómez, M. J., Conde‐Garrosa, R., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002054 · Cited by 48
Chen, D., Wang, J., Li, Y., Xu, C., Meng, F., Zhang, P., & Liu, L. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1418 · Cited by 46
Epidemiology, pathophysiology and clinical aspects of Hepatocellular Carcinoma in MAFLD patients
Argenziano, M. E., Kim, M. N., Montori, M., Bucchianico, A. D., Balducci, D., Ahn, S. H., & Svegliati‐Baroni, G. (2024) · Hepatology International · doi:10.1007/s12072-024-10692-4 · Cited by 52
Targeting RNA N6-methyladenosine modification: a precise weapon in overcoming tumor immune escape
Li, W., Hao, Y., Zhang, X., Xu, S., & Pang, D. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01652-3 · Cited by 46
Leung, R. W. H., & Lee, T. K. (2022) · Cancers · doi:10.3390/cancers14215468 · Cited by 50
Wnt/β-Catenin signaling pathway in hepatocellular carcinoma: pathogenic role and therapeutic target
Zhao, Z., Cui, T., Wei, F., Zhou, Z., Sun, Y., Gao, C., Xu, X., & Zhang, H. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1367364 · Cited by 47
Annexin A2 promotion of hepatocellular carcinoma tumorigenesis via the immune microenvironment
Qiu, L., Liu, Y., Cao, X., Wang, Y., Cui, X.-H., Ye, X., Huang, S.-W., Xie, H., & Zhang, H. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i18.2126 · Cited by 45
Role of Alpha-Fetoprotein in Hepatocellular Carcinoma Drug Resistance
Li, W., Liu, K., Chen, Y., Zhu, M., & Li, M. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327999200729151247 · Cited by 45
Extracellular vesicles in pancreatic cancer immune escape: Emerging roles and mechanisms
Liu, C., He, D., Li, L., Zhang, S., Wang, L., Fan, Z., & Wang, Y. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106364 · Cited by 44
miR-22 gene therapy treats HCC by promoting anti-tumor immunity and enhancing metabolism
Hu, Y., Setayesh, T., Vaziri, F., Wu, X., Hwang, S. T., Chen, X., & Wan, Y. Y. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.04.019 · Cited by 46
Zhou, Z., Li, X., Yang, G., Wang, J., Li, B., Huang, Y., Yan, J., & Tao, K. (2023) · Theranostics · doi:10.7150/thno.83377 · Cited by 45
Yü, Y., Zhang, C., Dong, B., Zhang, Z., Li, X., Huang, S., Tang, D., Jing, X.-W., Yu, S., Zheng, T., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217098 · Cited by 45
Tzeng, S.-F., Yu, Y.-R., Park, J., von Renesse, J., Hsiao, H.-W., Hsu, C.-H., Garnica, J., Chen, J., Chiu, L.-T., Santol, J., et al. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-1409 · Cited by 49
Tao, S., Liang, S., Zeng, T., & Yin, D. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1043667 · Cited by 46
Ramirez, C. F. A., Taranto, D., Ando‐Kuri, M., de Groot, M. H. P., Tsouri, E., Huang, Z., de Groot, D., Kluin, R. J. C., Kloosterman, D. J., Verheij, J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46835-2 · Cited by 42
Extracellular Vesicles and Their Current Role in Cancer Immunotherapy
Giacobino, C., Canta, M., Fornaguera, C., Borrós, S., & Cauda, V. (2021) · Cancers · doi:10.3390/cancers13092280 · Cited by 43
The Role of Fibroblast Growth Factor 19 in Hepatocellular Carcinoma
Chen, Z., Jiang, L., Liang, L., Koral, K., Zhang, Q., Zhao, L., Lu, S., & Tao, J. (2021) · American Journal Of Pathology · doi:10.1016/j.ajpath.2021.04.014 · Cited by 43
Association between abnormal lipid metabolism and tumor
Li, C., Wang, F., Cui, L., Li, S., Zhao, J., & Liao, L. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1134154 · Cited by 42
The Endless Sources of Hepatocellular Carcinoma Heterogeneity
Bárcena‐Varela, M., & Lujambio, A. (2021) · Cancers · doi:10.3390/cancers13112621 · Cited by 43
Self-citationLiu, F., Gai, X., Wu, Y., Zhang, B., Wu, X., Cheng, R., Tang, B., Shang, K., Zhao, N., Deng, W., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2202157119 · Cited by 41
Zhang, P., Du, Y., Bai, H., Wang, Z., Duan, J., Wang, X., Zhong, J. Y., Wan, R., Xu, J., He, X., et al. (2022) · BMC Medicine · doi:10.1186/s12916-022-02598-5 · Cited by 40
Metadata
- Authors
- Ruiz de Galarreta, M., Bresnahan, E., Molina-Sánchez, P., Lindblad, K. E., Maier, B., Sia, D., Puigvehi, M., Miguela, V., Casanova-Acebes, M., Dhainaut, M., Villacorta-Martin, C., Singhi, A. D., Moghe, A., von Felden, J., Tal Grinspan, L., Wang, S., Kamphorst, A. O., Monga, S. P., Brown, B. D., Villanueva, A., Llovet, J. M., Merad, M., & Lujambio, A.
- Affiliations
- 1Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York.
- Tisch Cancer Institute (US)
- Icahn School of Medicine at Mount Sinai (US)
- 2Liver Cancer Program, Division of Liver Diseases, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
- University of Pittsburgh (US)
- Institució Catalana de Recerca i Estudis Avançats (ES)
- Corresponding author
- Lujambio, Amaia
- ORCID
- Ruiz de Galarreta, Marina
- Molina-Sánchez, Pedro
- Lindblad, Katherine E.
- Maier, Barbara
- Sia, Daniela
- Puigvehi, Marc
- Miguela, Verónica
- Casanova-Acebes, María
- Dhainaut, Maxime
- Singhi, Aatur D.
- Moghe, Akshata
- von Felden, Johann
- Wang, Shuang
- Kamphorst, Alice O.
- Monga, Satdarshan P.
- Brown, Brian D.
- Villanueva, Augusto
- Llovet, Josep M.
- Lujambio, Amaia
- Venue
- Cancer Discovery
- Published
- 2019-08-01
- Volume
- 9
- Issue
- 8
- Pages
- 1124-1141
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC6677618
- OpenAlex
- W2952311394
- Cited by
- 912
- References
- 67
- Citations by year
- 2026: 114 · 2025: 121 · 2024: 158 · 2023: 169 · 2022: 156 · 2021: 116 · 2020: 67 · 2019: 11
- FWCI
- 36.78
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- Locations
- Cancer Discovery (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Damon Runyon Cancer Research FoundationDamon Runyon Cancer Research Foundation (Damon Runyon) (DR52-18)
- HHS | NIH | National Cancer InstituteHHS | NIH | National Cancer Institute (NCI) (R37CA230636, P30 CA196521)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- β-catenin signaling, hepatocellular carcinoma, immune evasion, anti-PD-1 resistance, PD-1 inhibitors, tumor surveillance, c-Myc, Trp53, dendritic cell recruitment, T cell function, RANTES, chemokines, genetically engineered mouse models, immunotherapy biomarkers
- MeSH terms
- Antineoplastic Agents, Immunological, Animals, Dendritic Cells, Disease Models, Animal, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Oncogenes, Biomarkers, Tumor, Signal Transduction, Gene Expression, Treatment Outcome, CD8-Positive T-Lymphocytes, Drug Resistance, Neoplasm, Tumor Escape, Xenograft Model Antitumor Assays, Cell Line, Tumor, beta Catenin, Mice, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
